Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE in COPD
NCT03917914Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Jun 2020
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular diseases (CVD) comparing Bisoprolol with Placebo (2 arms). Primary endpoints: All-cause mortality at 24 months, Hospitalisation for COPD exacerbation at 24 months and 8 more. Started Jun 2020; status: completed.
02
Drugs
bisoprolol
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT03917914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917914.